文献速递精神分裂症与精神病性障碍

氯氮平与难治性精神分裂症的死亡及自伤风险

Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.
PubMed 文献 · Am J Psychiatry · 2017-07-28

基于1996年后2,370例难治性精神分裂症人群队列,随访至死亡、首次自伤、移民或2013年6月1日,采用时变治疗Cox回归分析。未用氯氮平者全因死亡风险高于用氯氮平者(HR 1.88,95%CI 1.16-3.05),自伤风险在其他抗精神病药治疗时也高于氯氮平(HR 1.36,95%CI 1.04-1.78)。

要点

  • 未用氯氮平者全因死亡风险约为用氯氮平者的1.88倍。
  • 停用氯氮平后一年内死亡风险升高(HR 2.65,95%CI 1.47-4.78)。
  • 其他抗精神病药治疗时自伤风险高于氯氮平(HR 1.36,95%CI 1.04-1.78)。

核心结论

  • 难治性精神分裂症中未用氯氮平者全因死亡风险近乎为用氯氮平者的两倍。
  • 与其他抗精神病药相比,氯氮平治疗与更低的自伤风险相关。
  • 停用氯氮平后一年内超额死亡的原因尚待进一步研究。

研究设计与样本

  • 基于人群的队列研究,纳入1996年1月1日后2,370例难治性精神分裂症个体。
  • 随访至死亡、首次自伤、移民或2013年6月1日。
  • 采用时变治疗的Cox回归模型分析全因死亡与首次自伤时间,并校正临床与社会人口学协变量。

主要发现

  • 未用氯氮平者全因死亡风险高于用氯氮平者(HR 1.88,95%CI 1.16-3.05)。
  • 该差异主要来自无抗精神病药治疗期(HR 2.50,95%CI 1.50-4.17);其他抗精神病药治疗期死亡风险无统计学显著升高(HR 1.45,95%CI 0.86-2.45)。
  • 停用氯氮平后一年内观察到超额死亡(HR 2.65,95%CI 1.47-4.78)。
  • 其他抗精神病药治疗时自伤风险高于氯氮平(HR 1.36,95%CI 1.04-1.78)。

关键数值与推荐

  • 全因死亡:未用氯氮平 vs 用氯氮平 HR 1.88(95%CI 1.16-3.05)。
  • 无抗精神病药治疗期死亡 HR 2.50(95%CI 1.50-4.17);其他抗精神病药治疗期 HR 1.45(95%CI 0.86-2.45)。
  • 停用氯氮平后一年内死亡 HR 2.65(95%CI 1.47-4.78)。
  • 自伤:其他抗精神病药 vs 氯氮平 HR 1.36(95%CI 1.04-1.78)。

临床怎么用

  • 对难治性精神分裂症应重视氯氮平在降低死亡与自伤风险中的潜在获益。
  • 停用氯氮平后一年内需加强监测与随访,警惕死亡风险升高。
  • 无抗精神病药治疗期死亡风险最高,应尽量避免治疗中断。

局限性

  • 停用氯氮平后超额死亡可能受不依从及其他未观测因素混杂。
  • 尚不清楚超额死亡在多大程度上由近期氯氮平暴露的不良反应或停药后躯体/精神健康恶化所介导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated rates of all-cause mortality and self-harm in association with clozapine treatment in individuals with treatment-resistant schizophrenia. METHOD: A population-based cohort of 2,370 individuals with treatment-resistant schizophrenia after Jan. 1, 1996, was followed until death, first episode of self-harm, emigration, or June 1, 2013. Time to all-cause death and time to first episode of self-harm were analyzed in Cox regression models with time-varying treatment, adjusted for clinical and sociodemographic covariates. RESULTS: The rate of all-cause mortality was higher for patients not receiving clozapine than for those given clozapine (hazard ratio: 1.88, 95% confidence interval [CI]: 1.16-3.05). This was driven mainly by periods of no antipsychotic treatment (hazard ratio: 2.50, 95% CI: 1.50-4.17), with nonsignificantly higher mortality during treatment with other antipsychotics (hazard ratio: 1.45, 95% CI: 0.86-2.45). Excess mortality was observed in the year after clozapine discontinuation (hazard ratio: 2.65, 95% CI: 1.47-4.78). The rate of self-harm was higher for nonclozapine antipsychotics than for clozapine (hazard ratio: 1.36, 95% CI: 1.04-1.78). CONCLUSIONS: The results demonstrate a nearly twofold higher mortality rate among individuals with treatment-resistant schizophrenia not treated with clozapine compared with clozapine-treated individuals. Furthermore, the results suggest a harmful effect of other antipsychotics regarding self-harm compared with clozapine. It remains to be investigated to what extent the observed excess mortality after clozapine discontinuation is confounded by nonadherence and other unobserved factors and to what extent it is mediated by adverse effects from recent clozapine exposure or deterioration in physical or mental health precipitated by clozapine discontinuation.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wimberley T, MacCabe JH, Laursen TM, et al. Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. Am J Psychiatry. 2017. PMID: 28750580. doi:10.1176/appi.ajp.2017.16091097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。